{"downloaded": true, "htmlmade": false, "full": {"id": "29305552", "source": "MED", "pmid": "29305552", "pmcid": "PMC5922273", "fullTextIdList": {"fullTextId": "PMC5922273"}, "doi": "10.1182/blood-2017-06-788133", "title": "Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.", "authorString": "Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS.", "authorList": {"author": [{"fullName": "Coutre S", "firstName": "Steven", "lastName": "Coutre", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA."}}}, {"fullName": "Choi M", "firstName": "Michael", "lastName": "Choi", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California San Diego, San Diego, CA."}}}, {"fullName": "Furman RR", "firstName": "Richard R", "lastName": "Furman", "initials": "RR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Weill Cornell Medicine, New York, NY."}}}, {"fullName": "Eradat H", "firstName": "Herbert", "lastName": "Eradat", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology-Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA."}}}, {"fullName": "Heffner L", "firstName": "Leonard", "lastName": "Heffner", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Emory University School of Medicine, Atlanta, GA."}}}, {"fullName": "Jones JA", "firstName": "Jeffrey A", "lastName": "Jones", "initials": "JA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, The Ohio State University, Columbus, OH."}}}, {"fullName": "Chyla B", "firstName": "Brenda", "lastName": "Chyla", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Zhou L", "firstName": "Lang", "lastName": "Zhou", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Agarwal S", "firstName": "Suresh", "lastName": "Agarwal", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0003-3786-9773"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Waskiewicz T", "firstName": "Tina", "lastName": "Waskiewicz", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Verdugo M", "firstName": "Maria", "lastName": "Verdugo", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Humerickhouse RA", "firstName": "Rod A", "lastName": "Humerickhouse", "initials": "RA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Potluri J", "firstName": "Jalaja", "lastName": "Potluri", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "AbbVie Inc., North Chicago, IL."}}}, {"fullName": "Wierda WG", "firstName": "William G", "lastName": "Wierda", "initials": "WG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Texas MD Anderson Cancer Center, Houston, TX; and."}}}, {"fullName": "Davids MS", "firstName": "Matthew S", "lastName": "Davids", "initials": "MS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dana-Farber Cancer Institute, Boston, MA."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-3786-9773"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "15", "volume": "131", "journalIssueId": "2672597", "dateOfPublication": "2018 Apr", "monthOfPublication": "4", "yearOfPublication": "2018", "printPublicationDate": "2018-04-01", "journal": {"title": "Blood", "ISOAbbreviation": "Blood", "medlineAbbreviation": "Blood", "NLMid": "7603509", "ISSN": "0006-4971", "ESSN": "1528-0020"}}, "pubYear": "2018", "pageInfo": "1704-1711", "abstractText": "B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib; here we report on patients who received idelalisib as the last BCRi before enrollment. Venetoclax was initiated at 20 mg daily, followed by intrapatient ramp-up to 400 mg daily. Primary objectives included efficacy (objective response rate [ORR]) and safety of venetoclax. The study enrolled 36 patients who previously received idelalisib (ORR, 67% [24/36]); 2 patients achieved complete remission, and 1 had complete remission with incomplete bone marrow recovery. Median progression-free survival (PFS) has not yet been reached; estimated 12-month PFS was 79%. The most common adverse events (AEs; all grades) were neutropenia (56%), diarrhea (42%), upper respiratory tract infection (39%), thrombocytopenia (36%), nausea (31%), fatigue (28%), cough (22%), rash (22%), and anemia (22%). Grade 3 or 4 AEs were primarily hematologic (neutropenia [50%], thrombocytopenia [25%], and anemia [17%]). No patients experienced tumor lysis syndrome. Venetoclax demonstrated promising clinical activity and favorable tolerability in patients with CLL whose disease progressed during or after idelalisib therapy. This trial was registered at www.clinicaltrials.gov as #NCT02141282.", "affiliation": "Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Sulfonamides", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Purines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Proto-Oncogene Proteins c-bcl-2", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Administration, Oral"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Quinazolinones", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Lymphocytic, Chronic, B-Cell", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Bridged Bicyclo Compounds, Heterocyclic", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}]}, "chemicalList": {"chemical": [{"name": "Purines", "registryNumber": "0"}, {"name": "Sulfonamides", "registryNumber": "0"}, {"name": "Proto-Oncogene Proteins c-bcl-2", "registryNumber": "0"}, {"name": "Quinazolinones", "registryNumber": "0"}, {"name": "idelalisib", "registryNumber": "YG57I8T5M0"}, {"name": "BCL2 protein, human", "registryNumber": "0"}, {"name": "Bridged Bicyclo Compounds, Heterocyclic", "registryNumber": "0"}, {"name": "venetoclax", "registryNumber": "N54AIC43PW"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2017-06-788133"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5922273"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/blood-2017-06-788133"}]}, "commentCorrectionList": {"commentCorrection": {"id": "29650729", "source": "MED", "reference": "Blood. 2018 Apr 12;131(15):1632-1633", "type": "Comment in", "orderIn": "1"}}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "N", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "35", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-05-14", "dateOfCreation": "2018-01-07", "firstIndexDate": "2018-01-07", "fullTextReceivedDate": "2020-07-09", "dateOfRevision": "2021-02-02", "electronicPublicationDate": "2018-01-05", "firstPublicationDate": "2018-01-05"}, "abstract": "B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib; here we report on patients who received idelalisib as the last BCRi before enrollment. Venetoclax was initiated at 20 mg daily, followed by intrapatient ramp-up to 400 mg daily. Primary objectives included efficacy (objective response rate [ORR]) and safety of venetoclax. The study enrolled 36 patients who previously received idelalisib (ORR, 67% [24/36]); 2 patients achieved complete remission, and 1 had complete remission with incomplete bone marrow recovery. Median progression-free survival (PFS) has not yet been reached; estimated 12-month PFS was 79%. The most common adverse events (AEs; all grades) were neutropenia (56%), diarrhea (42%), upper respiratory tract infection (39%), thrombocytopenia (36%), nausea (31%), fatigue (28%), cough (22%), rash (22%), and anemia (22%). Grade 3 or 4 AEs were primarily hematologic (neutropenia [50%], thrombocytopenia [25%], and anemia [17%]). No patients experienced tumor lysis syndrome. Venetoclax demonstrated promising clinical activity and favorable tolerability in patients with CLL whose disease progressed during or after idelalisib therapy. This trial was registered at www.clinicaltrials.gov as #NCT02141282.", "journaltitle": "Blood", "authorinfo": ["Coutre S", "Choi M", "Furman RR", "Eradat H", "Heffner L", "Jones JA", "Chyla B", "Zhou L", "Agarwal S", "Waskiewicz T", "Verdugo M", "Humerickhouse RA", "Potluri J", "Wierda WG", "Davids MS"], "title": "Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy."}